丽珠医药LIVZON品牌怎么样申请店铺

我要投票

丽珠医药LIVZON在医疗用品行业中的票数：440 更新时间：2025-06-27

丽珠医药LIVZON是哪个国家的品牌？「丽珠医药LIVZON」是丽珠医药集团股份有限公司旗下著名品牌。该品牌发源于广东省珠海市，由创始人朱董在1985年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力丽珠医药LIVZON品牌出海！将品牌入驻外推网，定制丽珠医药LIVZON品牌推广信息，可以显著提高丽珠医药LIVZON产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

始于1985年，集医药研发/生产/销售为一体的公司，产品涉及消化/心脑血管/抗感染/抗肿瘤/生殖内分泌/中药/免疫治疗等领域

丽珠医药集团股份有限公司创建于1985年1月，注册资本为7.19亿元，截止2018年，公司总资产170亿元人民币，年度营业收入88.61亿元，扣非归母净利润9.47亿元，研发投入6.87亿元。1993年，丽珠A、B股相继上市；2014年新年伊始，公司完成了B股转H股，是资本市场上为数不多的A+H股医药上市公司。

丽珠集团拥有完备的现代化产业链和产品群，主要以化学药、中成药、原料药、微球、诊断试剂等多领域集群发力，在产在销的产品涉及消化、心脑血管、抗感染、抗肿瘤、生殖内分泌、中药、免疫治疗等领域。

丽珠集团以专注于人类生命健康事业为神圣使命，以提供特色专科药为目标，带动以“患者为中心”的医疗方式，进而实现向生物制药企业的战略转型。

Started in 1985, it is a company integrating pharmaceutical R & D / production / sales. Its products involve digestion / cardio cerebrovascular / anti infection / anti-tumor / reproductive endocrine / traditional Chinese medicine / immunotherapy and other fields. Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 719 million yuan. As of 2018, the company's total assets are 17 billion yuan, and its annual operating revenue is 8.861 billion yuan, net of non attributable to the mother The profit is 947 million yuan, and the R & D investment is 687 million yuan. In 1993, Lizhu A and B shares were listed successively; at the beginning of 2014, the company completed the conversion of B shares to H shares, which is one of the few a + H pharmaceutical listed companies in the capital market. Lizhu group has a complete modern industrial chain and product group, mainly focusing on chemical medicine, proprietary Chinese medicine, APIs, microspheres, diagnostic reagents and other fields. The products in production and marketing involve digestion, cardio cerebrovascular, anti infection, anti-tumor, reproductive endocrine, traditional Chinese medicine, immunotherapy and other fields. With the sacred mission of focusing on the cause of human life and health, and with the goal of providing characteristic specialty drugs, Lizhu group promotes the "patient-centered" medical treatment mode, so as to realize the strategic transformation to Biopharmaceutical Enterprises.

本文链接： https://brand.waitui.com/1e599e74d.html 联系电话：请联系客服添加联系邮箱：请联系客服添加